retatrutide clinical trial phase retatrutide ESC 2024: improves lipid and cardiovascular risk profile in II Retatrutide clinical trial done! Now
Description
Wegovy (Semaglutide Injection) Wegovy, the weight loss version of semaglutide, shares its active ingredient with Ozempic
Some people cannot tolerate the medication, have health conditions that make it unsuitable, or need a different approach
As of June 2026, retatrutide (LY3437943) is not approved in any country
Severe, persistent abdominal painespecially radiating to the back with nausea and vomitingmay indicate acute pancreatitis
Lillys public status language says retatrutide is available only to participants in Lilly-sponsored clinical trials, and current studies in obesity and weight management are part of a path aiming toward possible approval in 20262027
